These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 16619496

  • 1. P53R2, p53 inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer.
    Uramoto H, Sugio K, Oyama T, Hanagiri T, Yasumoto K.
    Anticancer Res; 2006; 26(2A):983-8. PubMed ID: 16619496
    [Abstract] [Full Text] [Related]

  • 2. Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer.
    Hsu NY, Wu JY, Liu X, Yen Y, Chen CY, Chou MC, Lin CH, Lee H, Cheng YW.
    Anticancer Res; 2011 Oct; 31(10):3475-81. PubMed ID: 21965764
    [Abstract] [Full Text] [Related]

  • 3. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L, Orre LM, Kanter L, Pernemalm M, Koyi H, Lewensohn R, Lehtiö J.
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of high-risk human papillomavirus oncoproteins on p53R2 gene expression after DNA damage.
    Lembo D, Donalisio M, Cornaglia M, Azzimonti B, Demurtas A, Landolfo S.
    Virus Res; 2006 Dec; 122(1-2):189-93. PubMed ID: 16872707
    [Abstract] [Full Text] [Related]

  • 7. Y-box-binding protein-1 expression is not correlated with p53 expression but with proliferating cell nuclear antigen expression in non-small cell lung cancer.
    Yoshimatsu T, Uramoto H, Oyama T, Yashima Y, Gu C, Morita M, Sugio K, Kohno K, Yasumoto K.
    Anticancer Res; 2005 Dec; 25(5):3437-43. PubMed ID: 16101161
    [Abstract] [Full Text] [Related]

  • 8. A lack of prognostic significance regarding DeltaNp63 immunoreactivity in lung cancer.
    Iwata T, Uramoto H, Sugio K, Fujino Y, Oyama T, Nakata S, Ono K, Morita M, Yasumoto K.
    Lung Cancer; 2005 Oct; 50(1):67-73. PubMed ID: 15950316
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint.
    Yamaguchi T, Matsuda K, Sagiya Y, Iwadate M, Fujino MA, Nakamura Y, Arakawa H.
    Cancer Res; 2001 Nov 15; 61(22):8256-62. PubMed ID: 11719458
    [Abstract] [Full Text] [Related]

  • 11. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
    Zhao ZH, Wang SF, Yu L, Wang J, Chang H, Yan WL, Zhang J, Fu K.
    Lung Cancer; 2008 Oct 15; 62(1):113-9. PubMed ID: 18550205
    [Abstract] [Full Text] [Related]

  • 12. p53R2 is a prognostic factor of melanoma and regulates proliferation and chemosensitivity of melanoma cells.
    Matsushita S, Ikeda R, Fukushige T, Tajitsu Y, Gunshin K, Okumura H, Ushiyama M, Akiyama S, Kawai K, Takeda Y, Yamada K, Kanekura T.
    J Dermatol Sci; 2012 Oct 15; 68(1):19-24. PubMed ID: 22902076
    [Abstract] [Full Text] [Related]

  • 13. Expression level of valosin-containing protein (p97) is correlated with progression and prognosis of non-small-cell lung carcinoma.
    Yamamoto S, Tomita Y, Hoshida Y, Iizuka N, Monden M, Yamamoto S, Iuchi K, Aozasa K.
    Ann Surg Oncol; 2004 Jul 15; 11(7):697-704. PubMed ID: 15231524
    [Abstract] [Full Text] [Related]

  • 14. Ribonucleotide reductase small subunit p53R2 facilitates p21 induction of G1 arrest under UV irradiation.
    Xue L, Zhou B, Liu X, Heung Y, Chau J, Chu E, Li S, Jiang C, Un F, Yen Y.
    Cancer Res; 2007 Jan 01; 67(1):16-21. PubMed ID: 17210678
    [Abstract] [Full Text] [Related]

  • 15. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer.
    Woenckhaus M, Merk J, Stoehr R, Schaeper F, Gaumann A, Wiebe K, Hartmann A, Hofstaedter F, Dietmaier W.
    Hum Pathol; 2008 Jan 01; 39(1):126-36. PubMed ID: 17949785
    [Abstract] [Full Text] [Related]

  • 16. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer.
    Zhang Z, Ma J, Li N, Sun N, Wang C.
    Ann Thorac Surg; 2006 Jul 01; 82(1):243-8. PubMed ID: 16798222
    [Abstract] [Full Text] [Related]

  • 17. Prognostic significance of Ape1/ref-1 subcellular localization in non-small cell lung carcinomas.
    Puglisi F, Aprile G, Minisini AM, Barbone F, Cataldi P, Tell G, Kelley MR, Damante G, Beltrami CA, Di Loreto C.
    Anticancer Res; 2001 Jul 01; 21(6A):4041-9. PubMed ID: 11911289
    [Abstract] [Full Text] [Related]

  • 18. Do bone marrow isolated tumor cells influence long-term survival of non-small cell lung cancer?
    Ruffato A, Mattioli S, Pileri S, Daddi N, D'Ovidio F, Pilotti V, Tazzari P.
    Eur J Cardiothorac Surg; 2009 Mar 01; 35(3):463-8. PubMed ID: 19150243
    [Abstract] [Full Text] [Related]

  • 19. Expression of the p53 family in lung cancer.
    Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Nozoe T, Yasumoto K.
    Anticancer Res; 2006 Mar 01; 26(3A):1785-90. PubMed ID: 16827107
    [Abstract] [Full Text] [Related]

  • 20. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
    Tsubochi H, Sato N, Hiyama M, Kaimori M, Endo S, Sohara Y, Imai T.
    Ann Thorac Surg; 2006 Oct 01; 82(4):1198-204. PubMed ID: 16996907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.